D2R awards $5.74 million in Translational Impact Research funding
Montreal 鈥� April 29, 2026 | 涩里番鈥檚 DNA to RNA Initiative (D2R) has invested nearly $6 million in funding to support four groundbreaking research projects that will advance RNA-based therapies for cancer and rare genetic diseases. The awards were initially announced at the D2R Research Symposium on April 23-24, 2026.
顿2搁鈥檚 Translational Impact Research (TIR) funding program supports large-scale, translational research projects that will have a measurable impact on the health of Canadians. By addressing gaps in current treatment options, these projects will accelerate the development of RNA-based therapies and make personalized medicine more accessible for patients with rare diseases and cancer.聽
The following Principal Investigators and their projects have been awarded funding:
- Charles Couturier 鈥� From Trial to Gene Therapy: Restoring Differentiation in IDH-Mutant Glioma
- Carl Ernst 鈥� mRNA therapy for CLN3 Batten disease
- Nada Jabado 鈥� From Bench to Bedside: RNA and AAV Gene Therapies for Diffuse Midline Gliomas
- Anastasia Nijnik 鈥� LNP/mRNA Therapy for Sickle Cell Disease